| Project/Area Number |
22591856
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
MASUYAMA Hisashi 岡山大学, 大学院・医歯薬学総合研究科, 准教授 (30314678)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRAMATSU Yuji 岡山大学, 大学院・医歯薬学総合研究科, 教 授 (80218817)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 卵巣癌 / 薬物耐性 / 核内受容体 |
|---|
| Research Abstract |
Recent studies have revealed that pregnane X receptor (PXR) can function as a master regulator to control the expression of drug-metabolizing enzymes, CYP3A family, as well as members of the drug transporter family, including MDR1. We observed that PXR-MDR pathway was expressed in various ovarian cancer tissues and that PXR down-regulation caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of the anti-cancer agents, paclitaxel, cisplatin. PXR down-regulation could be a novel therapeutic approach for the augmentation of sensitivity to anticancer agents, or to overcome resistance to them, in the treatment of ovarian cancer.
|
